المؤلفون: Ezcurra, Iranzu, Puente, Ángela, Cuadrado, Antonio, Tamayo, Ibai, Iruzubieta, Paula, Arias‐Loste, María Teresa, González, Francisco José, Pellón, Raúl, Sánchez, Sara, Crespo, Juan, Acebo, Mercedes, López‐Hoyos, Marcos, Pérez, Rocío, Cuesta, Amalia, Antón, Ángela, Echavarría, Víctor, Fábrega, Emilio, Crespo, Javier, Fortea, Jose Ignacio

المساهمون: Instituto de Salud Carlos III

المصدر: United European Gastroenterology Journal ; volume 11, issue 10, page 1010-1020 ; ISSN 2050-6406 2050-6414

الوصف: Background Preliminary evidence suggests that inherited hypercoagulable disorders can lead to an increased risk of significant liver fibrosis. Objective We aimed to investigate the prevalence of significant fibrosis in patients with inherited thrombophilia, assessed by using liver stiffness (LS), and to compare this prevalence to that found in a large population‐based cohort from the same region. Methods This was a single‐center, cross‐sectional study. A complete laboratory analysis for liver disease, LS by transient elastography and an abdominal ultrasound were performed in patients with inherited thrombophilia diagnosed between May 2013‐February 2017. These patients were propensity score matched (ratio 1:4) with a population‐based cohort from the same region (PREVHEP‐ETHON study; NCT02749864; N = 5988). Results Of 241 patients with inherited thrombophilia, eight patients (3.3%) had significant fibrosis (LS ≥8 kPa). All of them had risk factors for liver disease and met diagnostic criteria for different liver diseases. After matching 221 patients with thrombophilia with 884 patients of the PREVHEP‐ETHON cohort, the prevalence of significant fibrosis was similar between both cohorts (1.8% vs. 3.6%, p = 0.488). Multivariate analysis showed that age and liver disease risk factors, but not belonging to the thrombophilia cohort, were associated with the presence of significant fibrosis. The magnitude of the increased risk of significant fibrosis in patients with risk factors for liver disease was also similar in both cohorts. Conclusions Our findings do not provide evidence supporting an association between inherited thrombophilia and an increased risk of significant liver fibrosis, independent of the presence of liver‐related causes of fibrosis.

الإتاحة: https://doi.org/10.1002/ueg2.12500Test

المؤلفون: Rodriguez-Duque, Juan Carlos, Calleja, José Luis, Iruzubieta, Paula, Hernández-Conde, Marta, Rivas-Rivas, Coral, Vera, María Isabel, Garcia, Maria Jose, Pascual, Marta, Castro, Beatriz, García-Blanco, Agustín, García-Nieto, Enrique, Olmo, Soraya Curiel-del, Cagigal, María Luisa, Lopez-Montejo, Lorena, Fernández-Lamas, Tatiana, Rasines, Laura, Fortea, José Ignacio, Vaque, José Pedro, Frias, Yza, Rivero, Montserrat, Arias-Loste, María Teresa, Crespo, Javier

المساهمون: ISCIII

المصدر: Clinical Gastroenterology and Hepatology ; volume 21, issue 2, page 406-414.e7 ; ISSN 1542-3565

مصطلحات موضوعية: Gastroenterology, Hepatology

الإتاحة: https://doi.org/10.1016/j.cgh.2022.01.039Test
https://api.elsevier.com/content/article/PII:S1542356522000933?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1542356522000933?httpAccept=text/plainTest

المؤلفون: Bassegoda, Octavi, Olivas, Pol, Turco, Laura, Mandorfer, Mattias, Serra-Burriel, Miquel, Tellez, Luis, Kwanten, Wilhelmus, Laroyenne, Alexia, Farcau, Oana, Alvarado, Edilmar, Moga, Lucile, Vuille-Lessard, Elise, Fortea, Jose Ignacio, Ibañez, Luis, Tosetti, Giulia, Vanwolleghem, Thomas, Larrue, Hélène, Burgos-Santamaría, Diego, Stefanescu, Horia, Paternostro, Rafael, Cippitelli, Annalisa, Lens, Sabela, Augustin, Salvador, Llop, Elba, Laleman, Wim, Trebicka, Jonel, Chang, Johannes, Masnou, Helena, Zipprich, Alexander, Miceli, Francesca, Semmler, Georg, Forns, Xavier, Primignani, Massimo, Bañares, Rafael, Puente, Angela, Berzigotti, Annalisa, Rautou, Pierre Emmanuel, Villanueva, Candid, Gines, Pere, Garcia-Pagan, J C, Procopet, Bogdan, Bureau, Cristophe, Albillos, Agustin, Francque, Sven, Reiberger, Thomas, Schepis, Filippo, Graupera, Isabel, Hernandez-Gea, Virginia

المصدر: Bassegoda, Octavi; Olivas, Pol; Turco, Laura; Mandorfer, Mattias; Serra-Burriel, Miquel; Tellez, Luis; Kwanten, Wilhelmus; Laroyenne, Alexia; Farcau, Oana; Alvarado, Edilmar; Moga, Lucile; Vuille-Lessard, Elise; Fortea, Jose Ignacio; Ibañez, Luis; Tosetti, Giulia; Vanwolleghem, Thomas; Larrue, Hélène; Burgos-Santamaría, Diego; Stefanescu, Horia; Paternostro, Rafael; . (2022). Decompensation in advanced non-alcoholic fatty liver disease may occur at lower hepatic venous pressure gradient levels that in patients with viral disease. Clinical gastroenterology and hepatology, 20(10), 2276-2286.e6. Elsevier 10.1016/j.cgh.2021.10.023

مصطلحات موضوعية: 610 Medicine & health

الوصف: BACKGROUND & AIMS Portal hypertension (PH) is the strongest predictor of hepatic decompensation and death in patients with cirrhosis. However, its discriminatory accuracy in patients with non-alcoholic fatty liver disease (NAFLD) has been challenged as hepatic vein catheterization may not reflect the real portal vein pressure as accurately as in patients with other etiologies. We aimed to evaluate the relationship between hepatic venous pressure gradient (HVPG) and presence of portal hypertension related decompensation in patients with advanced NAFLD (aNAFLD). METHODS Multicenter cross-sectional study including 548 patients with aNAFLD and 444 with advanced RNA-positive hepatitis C (aHCV) who had detailed portal hypertension evaluation (HVPG measurement, gastroscopy, and abdominal imaging). We examined the relationship between etiology, HVPG, and decompensation by logistic regression models. We also compared the proportions of compensated/decompensated patients at different HVPG levels. RESULTS Both cohorts, aNAFLD and aHVC, had similar baseline age, gender, Child-Pugh score, and MELD. Median HVPG was lower in the aNAFLD cohort (13 vs 15 mmHg) despite similar liver function and higher rates of decompensation in aNAFLD group (32% vs 25% p=0.019) than in the aHCV group. For any of the HVPG cutoff analyzed (<10, 10-12 or 12 mmHg) the prevalence of decompensation was higher in the aNAFLD than in the aHCV group. CONCLUSION Patients with aNAFLD have higher prevalence of portal hypertension related decompensation at any value of HVPG as compared to aHCV patients. Longitudinal studies aiming to identify HVPG thresholds able to predict decompensation and long-term outcomes in aNAFLD population are strongly needed.

وصف الملف: application/pdf

العلاقة: https://boris.unibe.ch/160799Test/

الإتاحة: https://doi.org/10.1016/j.cgh.2021.10.023Test
https://boris.unibe.ch/160799/1/1-s2.0-S1542356521011368-main.pdfTest
https://boris.unibe.ch/160799Test/

المؤلفون: Bassegoda, Octavi, Olivas, Pol, Turco, Laura, Mandorfer, Mattias, Serra-Burriel, Miquel, Tellez, Luis, Kwanten, Wilhelmus, Laroyenne, Alexia, Farcau, Oana, Alvarado, Edilmar, Moga, Lucile, Vuille-Lessard, Elise, Fortea, Jose Ignacio, Ibañez, Luis, Tosetti, Giulia, Vanwolleghem, Thomas, Larrue, Hélène, Burgos-Santamaría, Diego, Stefanescu, Horia, Paternostro, Rafael, Cippitelli, Annalisa, Lens, Sabela, Augustin, Salvador, Llop, Elba, Laleman, Wim, Trebicka, Jonel, Chang, Johannes, Masnou, Helena, Zipprich, Alexander, Miceli, Francesca, Semmler, Georg, Forns, Xavier, Primignani, Massimo, Bañares, Rafael, Puente, Angela, Berzigotti, Annalisa, Rautou, Pierre Emmanuel, Villanueva, Candid, Ginès, Pere, Garcia-Pagan, J.C., Procopet, Bogdan, Bureau, Cristophe, Albillos, Agustin, Francque, Sven, Reiberger, Thomas, Schepis, Filippo, Graupera, Isabel, Hernandez-Gea, Virginia

المصدر: 1542-3565 ; Clinical gastroenterology and hepatology

مصطلحات موضوعية: Human medicine

الوصف: Background & Aims Portal hypertension is the strongest predictor of hepatic decompensation and death in patients with cirrhosis. However, its discriminatory accuracy in patients with nonalcoholic fatty liver disease (NAFLD) has been challenged because hepatic vein catheterization may not reflect the real portal vein pressure as accurately as in patients with other etiologies. We aimed to evaluate the relationship between hepatic venous pressure gradient (HVPG) and presence of portal hypertension–related decompensation in patients with advanced NAFLD (aNAFLD). Methods Multicenter cross-sectional study included 548 patients with aNAFLD and 444 with advanced RNA-positive hepatitis C (aHCV) who had detailed portal hypertension evaluation (HVPG measurement, gastroscopy, and abdominal imaging). We examined the relationship between etiology, HVPG, and decompensation by logistic regression models. We also compared the proportions of compensated/decompensated patients at different HVPG levels. Results Both cohorts, aNAFLD and aHVC, had similar baseline age, gender, Child-Pugh score, and Model for End-Stage Liver Disease score. Median HVPG was lower in the aNAFLD cohort (13 vs 15 mmHg) despite similar liver function and higher rates of decompensation in aNAFLD group (32% vs 25%; P = .019) than in the aHCV group. For any of the HVPG cutoff analyzed (<10, 10–12, or 12 mmHg) the prevalence of decompensation was higher in the aNAFLD group than in the aHCV group. Conclusions Patients with aNAFLD have higher prevalence of portal hypertension–related decompensation at any value of HVPG as compared with aHCV patients. Longitudinal studies aiming to identify HVPG thresholds able to predict decompensation and long-term outcomes in aNAFLD population are strongly needed.

العلاقة: info:eu-repo/semantics/altIdentifier/isi/000899945100021

الإتاحة: https://doi.org/10.1016/J.CGH.2021.10.023Test
https://hdl.handle.net/10067/1849310151162165141Test
https://repository.uantwerpen.be/docstore/d:irua:10181Test

المؤلفون: Téllez, Luis, Sánchez Rodríguez, Eugenia, Rodríguez de Santiago, Enrique, Llovet, Laura, Gómez-Outomuro, Ana, Díaz-Fontenla, Fernando, Álvarez López, Patricia, García-Eliz, María, Amaral, Carla, Sánchez-Torrijos, Yolanda, Fortea, José Ignacio, Ferre-Aracil, Carlos, Rodríguez-Perálvarez, Manuel, Abadía, Marta, Gómez-Camarero, Judith, Olveira, Antonio, Calleja, José Luis, Crespo, Javier, Romero, Manuel, Hernández-Guerra, Manuel, Berenguer, Marina, Riveiro-Barciela, Mar, Salcedo, Magdalena, Rodríguez, Manuel, Londoño, María Carlota, Albillos, Agustín

مصطلحات موضوعية: Acute Disease, Adolescent, Adrenal Cortex Hormones, Ascites, Brain Diseases, Hepatitis, Autoimmune, Humans, Prognosis, Retrospective Studies, Severity of Illness Index

الوصف: To assess whether corticosteroids improve prognosis in patients with AS-AIH, and to identify factors at therapy initiation and during therapy predictive of the response to corticosteroids. This was a retrospective cohort study including all patients with AS-AIH admitted to 13 tertiary centres from January 2002 to January 2019. The composite primary outcome was death or liver transplantation within 90 days of admission. Kaplan-Meier and Cox regression methods were used for data analysis. Of 242 consecutive patients enrolled (mean age [SD] 49.7 [16.8] years), 203 received corticosteroids. Overall 90-day transplant-free survival was 61.6% (95% confidence interval [CI] 55.4-67.7). Corticosteroids reduced the risk of a poor outcome (adjusted hazard ratio [HR] 0.25; 95% CI 0.2-0.4), but this treatment failed in 30.5%. An internally validated nomogram composed of older age, MELD, encephalopathy and ascites at the initiation of corticosteroids accurately predicted the response (C-index 0.82; [95% CI 0.8-0.9]). In responders, MELD significantly improved from days 3 to 14 but remained unchanged in non-responders. MELD on day 7 with a cut-off of 25 (sensitivity 62.5%[95% CI: 47.0-75.8]; specificity 95.2% [95% CI: 89.9-97.8]) was the best univariate predictor of the response. Prolonging corticosteroids did not increase the overall infection risk (adjusted HR 0.75; 95% CI 0.3-2.1). Older patients with high MELD, encephalopathy or ascites at steroid therapy initiation and during treatment are unlikely to show a favourable response and so prolonged therapy in these patients, especially if they are transplantation candidates, should be avoided.

وصف الملف: application/pdf

العلاقة: http://hdl.handle.net/10668/19913Test; PMC9324977; https://repositorio.uam.es/bitstream/10486/705454/2/early_tellez_ap%26t_2022.pdfTest; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324977/pdfTest

الإتاحة: https://doi.org/10.1111/apt.16926Test
http://hdl.handle.net/10668/19913Test
https://repositorio.uam.es/bitstream/10486/705454/2/early_tellez_ap%26t_2022.pdfTest
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324977/pdfTest

المؤلفون: Cuadrado, Antonio, del Barrio, María, Fortea, José Ignacio, Amigo, Lidia, San Segundo, David, Rodriguez‐Cundin, María Paz, Rebollo, María Henar, Fernandez‐Santiago, Roberto, Castillo, Federico, Achalandabaso, Maria, Echeverri, Juan, Anderson, Edward J., Rodríguez‐Sanjuan, Juan Carlos, López‐Hoyos, Marcos, Crespo, Javier, Fábrega, Emilio

المصدر: Hepatology Communications ; volume 6, issue 7, page 1673-1679 ; ISSN 2471-254X 2471-254X

الوصف: Different reports have shown the clinical and serologic response to the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) messenger RNA (mRNA) vaccines in preventing coronavirus disease 2019 (COVID‐19) in the general population, but few studies have examined these responses in transplant recipients. We assessed the vaccine immunogenicity of two doses (100 μg) of the mRNA‐1273 vaccine (Moderna) administered with a 28‐day interval in liver transplant recipients (LTRs) at follow‐up at the Marques de Valdecilla University Hospital. LTRs without a history of COVID‐19 infection were tested for SARS‐CoV‐2 immunoglobulin G (IgG) antibodies directed against the spike protein (S) a median of 43 days after receiving the second Moderna vaccine dose. Clinical data, including immunosuppressive regimen and routine laboratory data, were obtained from the medical record of each patient up to 3 months before the date of the first vaccination. Factors associated with serologic response were evaluated through logistic regression. In total, 129 LTRs who had anti‐S results were included. Most patients were men (n = 99; 76.7%) with a median age of 63 years (interquartile range, 56–68). Alcohol (43.4%) and chronic hepatitis C (18.6%) were the most frequent causes of liver transplantation. A positive anti‐S IgG response was observed in 113 LTRs (87.6%; 95% confidence interval [CI], 80.8–92.2). A strong inverse relationship between mycophenolate mofetil use and serologic response was found (odds ratio, 0.07; 95% CI, 0.02–0.26; p = 0.001). Conclusion: Most LTRs develop an immunological response to the Moderna SARS‐CoV‐2 mRNA‐based vaccine. An immunosuppressive regimen that includes mycophenolate predicts a weak serologic response.

الإتاحة: https://doi.org/10.1002/hep4.1937Test

المؤلفون: Baiges, Anna, Cerda, Eira, Amicone, Caroline, Téllez, Luis, Alvarado-Tapias, Edilmar, Puente, Angela, Fortea, Jose Ignacio, Llop, Elba, Rocha, Filipa, Orts, Lara, Ros-Fargas, Oliva, Vizcarra, Pamela, Zekrini, Kamal, Lounes, Ould Amara, Touati, Ghiles, Jiménez-Esquivel, Natalia, Serrano, Maria Jose, Falgà, Angels, Magaz, Marta, Olivas, Pol, Betancourt, Fabian, Perez-Campuzano, Valeria, Turon, Fanny, Payancé, Audrey, Goria, Odile, Rautou, Pierre-Emmanuel, Hernández-Gea, Virginia, Villanueva, Candid, Albillos, Agustin, Plessier, Aurélie, García-Pagán, Juan-Carlos

المساهمون: AGAUR, Instituto de Salud Carlos III

المصدر: Clinical Gastroenterology and Hepatology ; volume 20, issue 7, page 1525-1533.e5 ; ISSN 1542-3565

مصطلحات موضوعية: Gastroenterology, Hepatology

الإتاحة: https://doi.org/10.1016/j.cgh.2021.12.032Test
https://api.elsevier.com/content/article/PII:S1542356521013562?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1542356521013562?httpAccept=text/plainTest

المؤلفون: Baiges Aznar, Anna, Cerda, Eira, Amicone, Caroline, Tellez, Luis, Alvarado Tapias, Edilmar, Puente, Angela, Fortea, Jose Ignacio, Llop, Elba, Rocha, Filipa, Orts, Lara, Ros Fargas, Olivia, Vizcarra, Pamela, Zekrini, Kamal, Amara Lounes, Ould, Touati, Ghiles, Jimenez, Natalia, Serrano, Maria Jose, Falgà, Àngels, Magaz Martínez, Marta, Olivas, Pol, Betancourt, Fabian, Pérez Campuzano, Valeria, Turon, Fanny, Payancé, Audrey, Goria, Odile, Rautou, Pierre Emmanuel, Hernández Gea, Virginia, Villanueva, Candid, Albillos, Agustín, Plessier, Aurélie, García Pagán, Juan Carlos

المصدر: Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

مصطلحات موضوعية: SARS-CoV-2, COVID-19, Malalties vasculars, Malalties del fetge, Vascular diseases, Liver diseases

الوصف: Vascular liver diseases (VLD) are represented mainly by portosinusoidal vascular disease (PSVD), non-cirrhotic splanchnic vein thrombosis (SVT) and Budd Chiari syndrome (BCS). It is unknown whether patients with VLD constitute a high-risk population for complications and greater COVID-19-related mortality from SARS-CoV-2 infection. Our objective was to assess the prevalence and severity of SARS-CoV-2 infection among patients with VLD, as well as to assess its impact on hepatic decompensation and survival.This is a observational international study analyzing the prevalence and severity of SARS-CoV-2 infection in VLD between March 2020-March 2021 comparing with the general population (GP). Patients from Spain (5 centers, n = 493) and France (1 center, n = 475) were included.Nine hundred and sixty-eight patients were included: 274 PSVD, 539 SVT and 155 BCS. Among them, 138 (14%) were infected with SARS-CoV-2: 53 PSVD, 77 SVT and 8 BCS. The prevalence of SARS-CoV-2 infection in PSVD (19%) and SVT (14%) was significantly higher than in GP (6.5%, p < 0.05), while it was very similar in BCS (5%). In terms of infection severity, patients with VLD also presented a higher need of hospital admission (14% vs 7.3%, p<0.01), ICU admission (2% vs 0.7%, p< 0.01) and mortality (4% vs 1.5%, p < 0.05) than GP. Previous history of ascites (50% vs 8%, p < 0.05) and post-COVID-19 hepatic decompensation (50% vs 4%, p < 0.05) were associated to COVID-19 mortality.PSVD and SVT patients could be at higher risk of infection by SARS-CoV-2 and at higher risk of severe COVID-19 disease.Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.

وصف الملف: 33 p.; application/pdf

العلاقة: versió postprint del document publicat a: https://doi.org/10.1016/j.cgh.2021.12.032Test; Clinical Gastroenterology And Hepatology, 2021; https://doi.org/10.1016/j.cgh.2021.12.032Test; http://hdl.handle.net/2445/182343Test; 9295622

الإتاحة: https://doi.org/10.1016/j.cgh.2021.12.032Test
http://hdl.handle.net/2445/182343Test

المؤلفون: Magaz, Marta, Giudicelli-Lett, Heloïse, Nicoară-Farcău, Oana, Rajoriya, Neil, Goel, Ashish, Raymenants, Karlien, Hillaire, Sophie, Crespo, Gonzalo, Téllez, Luis, Elkrief, Laure, Fondevila, Constantino, Orts, Lara, Nery, Filipe, Shukla, Akash, Larrue, Hélène, Fundora, Yiliam, Degroote, Helena, Aguilera, Victoria, LLop, Elba, Turco, Laura, Indulti, Federica, Gioia, Stefania, Tosetti, Giulia, Bitto, Niccolò, Becchetti, Chiara, Alvarado, Edilmar, Roig, Cristina, Diaz, Raquel, Praktiknjo, Michael, Konicek, Anna-Lena, Soy, Guillem, Olivas, Pol, Fortea, José Ignacio, Masnou, Helena, Puente, Ángela, Ardèvol, Alba, Álvarez-Navascués, Carmen, Romero, Marta, Scheiner, Bernhard, Semmler, Georg, Mandorfer, Mattias, Damião, Filipe, Baiges, Anna, Turon, Fanny, Simón-Talero, Macarena, González-Alayón, Carlos, Díaz, Alba, García-Criado, Ángeles, de Gottardi, Andrea, Reverter, Enric, Blasi, Annabel, Genescà, Joan, Roux, Olivier, Francoz, Claire, Noronha Ferreira, Carlos, Reiberger, Thomas, Rodríguez, Manuel, Morillas, Rosa María, Crespo, Javier, Trebicka, Jonel, Bañares, Rafael, Villanueva, Càndid, Berzigotti, Annalisa, Primignani, Massimo, La Mura, Vincenzo, Riggio, Oliviero, Schepis, Filippo, Procopet, Bogdan, Verhelst, Xavier, Calleja, José Luis, Bureau, Christophe, Albillos, Agustín, Nevens, Frederik, Hernández-Gea, Virginia, Tripathi, Dhiraj, Rautou, Pierre-Emmanuel, Durand, François, García-Pagán, Juan Carlos

المساهمون: Magaz, Marta, Giudicelli-Lett, Heloïse, Nicoară-Farcău, Oana, Rajoriya, Neil, Goel, Ashish, Raymenants, Karlien, Hillaire, Sophie, Crespo, Gonzalo, Téllez, Lui, Elkrief, Laure, Fondevila, Constantino, Orts, Lara, Nery, Filipe, Shukla, Akash, Larrue, Hélène, Fundora, Yiliam, Degroote, Helena, Aguilera, Victoria, Llop, Elba, Turco, Laura, Indulti, Federica, Gioia, Stefania, Tosetti, Giulia, Bitto, Niccolò, Becchetti, Chiara, Alvarado, Edilmar, Roig, Cristina, Diaz, Raquel, Praktiknjo, Michael, Konicek, Anna-Lena, Soy, Guillem, Olivas, Pol, Fortea, José Ignacio, Masnou, Helena, Puente, Ángela, Ardèvol, Alba, Álvarez-Navascués, Carmen, Romero, Marta, Scheiner, Bernhard, Semmler, Georg, Mandorfer, Mattia, Damião, Filipe, Baiges, Anna, Turon, Fanny, Simón-Talero, Macarena, González-Alayón, Carlo, Díaz, Alba, García-Criado, Ángele, de Gottardi, Andrea, Reverter, Enric, Blasi, Annabel, Genescà, Joan, Roux, Olivier, Francoz, Claire, Noronha Ferreira, Carlo, Reiberger, Thoma, Rodríguez, Manuel, Morillas, Rosa María, Crespo, Javier, Trebicka, Jonel, Bañares, Rafael, Villanueva, Càndid, Berzigotti, Annalisa, Primignani, Massimo, La Mura, Vincenzo, Riggio, Oliviero, Schepis, Filippo, Procopet, Bogdan, Verhelst, Xavier, Calleja, José Lui, Bureau, Christophe, Albillos, Agustín, Nevens, Frederik, Hernández-Gea, Virginia, Tripathi, Dhiraj, Rautou, Pierre-Emmanuel, Durand, Françoi, García-Pagán, Juan Carlos

الوصف: Background: Porto-sinusoidal vascular liver disorder (PSVD) is a rare disease that occasionally requires liver transplantation (LT), despite usually presenting preserved liver function. There remains a paucity of data pertaining to LT in PSVD. The aim was to identify features associated with post-LT outcomes in PSVD. Methods: Retrospective multicentre study of 79 patients who received LT for PSVD. Results: Median post-LT follow-up was 37 (range 1-261) mo. Refractory ascites 24 (30%), hepatic encephalopathy 16 (20%), and hepatopulmonary syndrome 13 (16.3%) were the most frequent indications for LT. Hepatocellular carcinoma was the indication in only 2 patients. Twenty-four patients died, 7 due to liver and 17 to non-liver related causes. Post-LT survival was 82.2%, 80.7%, and 68.6% at 1, 2, and 5 y, respectively. Post-LT survival was significantly better in patients without (n = 58) than in those with a persistent severe PSVD-associated condition (n = 21). Pre-LT hyperbilirubinemia levels and creatinine >100 μmol/L were also independently associated with poor survival. Six patients (7.6%) required a second LT. Recurrence of PSVD was confirmed by liver biopsy in only 1 patient and in 3 further patients it was likely. Conclusions: LT in PSVD is associated with an acceptable outcome in the absence of associated severe conditions. However, persistence of a severe associated condition, pre-LT high bilirubin levels, or creatinine >100 μmol/L impact outcome, and these are features that should be considered when evaluating PSVD patients for LT. PSVD recurrence is possible after LT and needs to be explored, at least, in cases of posttransplant portal hypertension.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36479977; info:eu-repo/semantics/altIdentifier/wos/WOS:001000965400030; volume:107; issue:6; firstpage:1330; lastpage:1340; journal:TRANSPLANTATION; https://hdl.handle.net/11380/1306716Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85160003503

الإتاحة: https://doi.org/10.1097/TP.0000000000004444Test
https://hdl.handle.net/11380/1306716Test

المؤلفون: Fortea, Jose Ignacio, Puente, Ángela, Cuadrado, Antonio, Huelin, Patricia, García, Inés, Mayorga, Marta, Pellon, Raul, Crespo, Javier, Fábrega, Emilio

المصدر: https://www.intechopen.com/books/7031Test.

مصطلحات موضوعية: Liver Pathology

الوصف: Liver disease resulting from heart disease has generally been referred as “cardiac hepatopathy.” The two main forms of cardiac hepatopathy are acute cardiogenic liver injury (ACLI) and congestive hepatopathy (CH). ACLI most commonly occurs in the setting of acute cardiocirculatory failure, whereas CH results from passive venous congestion in the setting of chronic right-sided heart failure (HF). Both conditions often coexist and potentiate the deleterious effects of each other on the liver. In CH, the chronic passive congestion leads to sinusoidal hypertension, centrilobular fibrosis, and ultimately, cirrhosis (“cardiac cirrhosis”) and hepatocellular carcinoma. The differentiation between congestion and fibrosis currently represents an unmet need and a growing research area. Although cardiac cirrhosis may only arise after several decades of ongoing injury, the long-term survival of cardiac patients due to advances in medical and surgical treatments is responsible for the increased number of liver complications in this setting. Eventually, the liver disease could become as clinically relevant as the cardiac disease and further complicate its management.

العلاقة: https://mts.intechopen.com/articles/show/title/cardiac-hepatopathyTest

الإتاحة: https://doi.org/10.5772/intechopen.89177Test
https://mts.intechopen.com/articles/show/title/cardiac-hepatopathyTest